1

8 - 10 JANUARY, 2021 VIRTUAL SUMMIT

APBCS E-BROCHURE

ORGANIZED BY

APBCS.ORG

ACCESS VIRTUAL PLATFORM

https://events.index.ae/apbcs-2021/login

2

CONTENTTABLE OF

Organizing & Scientific Committee 3

International Speakers 4

Regional Speakers 7

Local Speakers 9

Program at Glance 12

Best of San Antonio Breast Cancer Symposium Program 13

Oncology Nursing Session 15

APBCS Agenda - Day 1 16

APBCS Agenda - Day 2 18

Sponsors 23

3

SHAHEENAH DAWOODUAE

SHAHEENAH DAWOODUAE

REBECCA DENTSINGAPORE

LEE SOO CHINSINGAPORE

LEE SOO CHINSINGAPORE

NAN SOON WONG SINGAPORE

GEOK HOON LIM SINGAPORE

MAY LENG MABEL TAN SINGAPORE

ORGANIZING COMMITTEE

SCIENTIFIC COMMITTEE

REBECCA DENTSINGAPORE

4

ADAM BRUFSKYASSOCIATE CHIEF, DIVISION OF HEMATOLOGY/ONCOLOGY DIRECTOR, COMPREHENSIVE BREAST CANCER CENTER UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE USA

ADITYA BARDIAMOLECULAR ONCOLOGIST, MASSACHUSETTS GENERAL HOSPITAL USA

CHARLES PEROUPROFESSOR, LINEBERGER COMPREHENSIVE CANCER CENTER USA

DARCY BURBAGEONCOLOGY CLINICAL NURSE, CHRISTIANA CARE HEALTH SYSTEM USA

EVANDRO DE AZAMBUJA HEAD OF THE MEDICAL SUPPORT TEAM, JULES BORDET INSTITUTE BELGIUM

FABRICE ANDREMEDICAL ONCOLOGIST, INSTITUT GUSTAVE ROUSSY FRANCE

INTERNATIONAL SPEAKERS

5

GIUSEPPE CURIGLIANO ASSOCIATE PROFESSOR, UNIVERSITY OF MILANO ITALY

IAN KROP ASSOCIATE CHIEF DIVISION OF BREAST ONCOLOGY, DANA FARBER CANCER INSTITUTE USA

JAVIER CORTES MEDICAL ONCOLOGIST, HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL SPAIN

LISA CAREY PROFESSOR, NORTH CAROLINA CANCER HOSPITAL USA

MONICA MORROW SURGICAL ONCOLOGIST, MEMORIAL SLOAN KETTERING CANCER CENTER USA

NICHOLAS TURNER CONSULTANT MEDICAL ONCOLOGIST, THE INSTITUTE OF CANCER RESEARCH UNITED KINGDOM

6

PETER FASCHING ASSOCIATE PROFESSOR, UNIVERSITY HOSPITAL ERLANGEN AND COMPREHENSIVE CANCER CENTER GERMANY

PHILIP POORTMANS PROFESSOR, CURIE INSTITUTE BELGIUM

SANDRA SWAIN ASSOCIATE DEAN FOR RESEARCH DEVELOPMENT, PROFESSOR OF MEDICINE, GEORGETOWN UNIVERSITY MEDICAL CENTER USA

SHAHEENAH DAWOOD MEDICAL ONCOLOGIST, MEDICLINIC CITY HOSPITAL UNITED ARAB EMIRATES

STEPHEN JOHNSTON PROFESSOR, THE ROYAL MARSDEN NHS FOUNDATION TRUST UNITED KINGDOM

7

REGIONAL SPEAKERS

AMY CHOW ASSOCIATE PROFESSOR, DEPARTMENT OF SOCIAL WORK AND SOCIAL ADMINISTRATION - THE UNIVERSITY OF HONG KONG HONG KONG

JANICE TSANG SPECIALIST IN MEDICAL ONCOLOGY, LI KA SHING FACULTY OF MEDICINE, THE UNIVERSITY OF HONG KONG HONG KONG

JYOTI BAJPAI MEDICAL ONCOLOGIST, TATA MEMORIAL HOSPITAL INDIA

LU YEN SHEN CLINICAL PROFESSOR, NATIONAL TAIWAN UNIVERSITY TAIWAN

SEOCK-AH IM MEDICAL ONCOLOGIST, SEOUL NATIONAL UNIVERSITY COLLEGE OF MEDICINE SOUTH KOREA

SHERENE LOI MEDICAL ONCOLOGIST, PETER MACCALLUM CANCER CENTRE AUSTRALIA

8

SHOM GOEL CONSULTANT MEDICAL ONCOLOGIST, PETER MACCALLUM CANCER CENTRE AUSTRALIA

SHONA NAG CONSULTANT MEDICAL ONCOLOGIST, DIRECTOR OF ONCOLOGY, SAHYADRI GROUP OF HOSPITALS INDIA

VIROTE SRIURANPONG CHIEF, MEDICAL ONCOLOGY UNIT, CHULALONGKORN UNIVERSITY THAILAND

YEON HEE PARK MEDICAL ONCOLOGIST, SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE SOUTH KOREA

9

LOCAL SPEAKERS

ELAINE LIM SENIOR CONSULTANT, NATIONAL CANCER CENTRE SINGAPORE (NCCS) SINGAPORE

IAIN TAN MEDICAL ONCOLOGIST, NATIONAL CANCER CENTRE SINGAPORE (NCCS) SINGAPORE

JACK CHAN CONSULTANT, NATIONAL CANCER CENTRE SINGAPORE (NCCS) SINGAPORE

JOLINE LIM CONSULTANT, DEPARTMENT OF HAEMATOLOGY-ONCOLOGY, NATIONAL UNIVERSITY CANCER INSTITUTE SINGAPORE

LEE SOO CHIN MEDICAL ONCOLOGIST, NATIONAL UNIVERSITY CANCER INSTITUTE SINGAPORE

MAY LENG MABEL TAN ADVANCED PRACTICE NURSE, NATIONAL CANCER CENTRE SINGAPORE (NCCS)SINGAPORE

10

REBECCA DENT SENIOR CONSULTANT, NATIONAL CANCER CENTRE SINGAPORE (NCCS SINGAPORE

SAMUEL OW CONSULTANT MEDICAL ONCOLOGIST, NATIONAL UNIVERSITY CANCER INSTITUTESINGAPORE

TAN PUAY HOON MEDICAL ONCOLOGIST, SINGAPORE GENERAL HOSPITAL SINGAPORE

TIRA TAN CONSULTANT, DIVISION OF MEDICAL ONCOLOGY, NATIONAL CANCER CENTRE SINGAPORE (NCCS) SINGAPORE

VERONIQUE TAN HEAD & SENIOR CONSULTANT BREAST SURGERY NATIONAL CANCER CENTRE SINGAPORE (NCCS) SINGAPORE

WONG NAN SOON MEDICAL ONCOLOGIST, GLENEAGLES HOSPITAL SINGAPORE

11

YAP YOON SIM SENIOR CONSULTANT, NATIONAL CANCER CENTRE SINGAPORE (NCCS) SINGAPORE

APBCS.ORG

12

SINGAPORE TIME

DAY ONE8th JANUARY, 2021

DAY TWO9th JANUARY, 2021

DAY THREE10th JANUARY, 2021

08:00 GOING LIVE

08:30

Oncology Nursing Session

09:30

10:30

11:30

12:30

13:00

13:30

14:00

14:00

14:30

15:30 GOING LIVE GOING LIVE GOING LIVE

16:00

Best of San Antonio Breast Cancer

Symposium

9th Asia-Pacific Breast Cancer

Summit

Day 1

9th Asia-Pacific Breast Cancer

Summit

Day 2

16:30

17:00

17:30

18:00 GOING LIVE

18:30

6th Singapore Breast Oncoplastic Surgery Symposium

(SBOSS)

19:00

19:30

20:00

20:30

21:00

21:30

22:00

22:30

PROGRAM AT A GLANCE

12

13

BEST OF SAN ANTONIO BREAST CANCER SYMPOSIUM PROGRAM

15:30 – 15:40 Topics Presented By: LIM GEOK HOON, SINGAPORE

Radioactive Iodine Seed placement in the Axilla with Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer: results of the prospective multicenter RISAS trial

15.40 – 15.45 Q & A

15.45 – 15.55 Topics Presented By: FAYE LIM, SINGAPORE

Prime 2 randomised trial (postoperative radiotherapy in minimum-risk elderly): wide local excision and adjuvant hormonal therapy +/- whole breast irradiation in women =/> 65 years with early invasive breast cancer:10 year results

A randomized phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (BIG 3-07/TROG 07.01)

15.55 – 16.00 Q & A

16.00 – 16.20 Topics Presented By: SHAHEENAH DAWOOD, UAE

Final invasive disease-free survival analysis of monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer

Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancer and with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B

12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ

16.20 – 16.25 Q & A

16.25 – 16.35 Topics Presented By: TIRA TAN, SINGAPORE

Neoadjuvant nab-paclitaxel weekly versus dose-dense paclitaxel followed by dose-dense EC in high risk HR+/HER2- early BC by: results from the neoadjuvant part of ADAPT HR+/HER2- trial

Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine benefit: a Trans-aTTom Study

16.35 – 16.40 Q & A

Friday, 8th January 2021

15.30 - 17.40 Singapore Time

14

16.40 – 17.05 Topics Presented By: WONG NAN SOON, SINGAPORE

Adjuvant trial randomized ER+ patients who had a Recurrence Score < 25 and 1-3 positive nodes to endocrine therapy (ET) versus ET + chemotherapy.

Development and validation of a tool integrating the 21-gene recurrence score and clinicopathlogic features to individualize prognosis for distant recurrence and prediction of absolute chemotherapy benefit in early breast cancer

How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status

Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score

15

ONCOLOGY NURSING SESSION

Saturday, 9th January 2021

8.30 - 13.00 Hrs Singapore Time

08:30 – 08:35 Welcome MABEL TAN MAY LENG

DNP, RN, ONC, NATIONAL CANCER CENTRE SINGAPORE

08:35 – 09:35 Overview of Breast Cancer Treatment DARCY BURBAGE

DNP, RN, AOCN, CBCN, CHRISTIANA CARE HEALTH SYSTEM, NEWARK, DELAWARE, USA

09:35 – 10:05 Management of Breast Cancer Surgical Side Effects DARCY BURBAGE

DNP, RN, AOCN, CBCN, CHRISTIANA CARE HEALTH SYSTEM, NEWARK, DELAWARE, USA

10:05 – 10:15 Break

10:15 – 11:15 Psychosocial Challenges and Management of Breast Cancer and Treatments AMY CHOW

PHD, RSW, FT, THE UNIVERSITY OF HONG KONG, HONG KONG

11:15 – 11:45 Small Group Case Studies Discussion Activity in Breakout Rooms FACILITATORS

(10 GROUPS)

11:45 – 12:55 Sharing by Small Group Facilitators or Representatives Comments by Speakers and Participants

MABEL TAN MAY LENG SINGAPORE

DARCY BURBAGE USA

AMY CHOW HONG KONG

12:55 – 13:00 Conclusion & Announcements MABEL TAN MAY LENG

SINGAPORE

16

APBCS AGENGA – DAY 1

15:50 – 15:55 Opening Remarks APBCS 2021 COMMITTEE

15:55 – 16:00 Session Introduction - YEON HEE PARK, SOUTH KOREA (Supported by MSD)

16:00 – 16:20 Advances of Immunotherapy in Neoadjuvant TNBCJAVIER CORTES, SPAIN

16:20 – 16:40 An Asian Perspective with Case studiesYEON HEE PARK, SOUTH KOREA

16:40 – 16:45 Q & A

SESSION 1: ER + Early Breast Cancer Chairperson: VERONIQUE TAN, SINGAPORE | YAP YOON SIM, SINGAPORE

16:45 – 17:05 Should all ER-pos Patients Receive 10 years of Endocrine Therapy?STEPHEN JOHNSTON, UK

17:05 – 17:25 Is it time to adopt CDK inhibitors in adjuvant setting? Critical evaluation of the literatureEVANDRO DE AZAMBUJA, BELGIUM

17:25 – 17:45 Q & A

SESSION 2: Early Breast Cancer Chairperson: ELAINE LIM, SINGAPORE | SHAHEENAH DAWOOD, UAE

17:45 – 18:05 Special Issues in Young Women with Early Breast Cancer JYOTI BAJPAI, INDIA

18:05 – 18:25 Personalised breast RT - Are we there yet? PHILIP POORTMANS, BELGIUM

18:25 – 18:45 What’s New in Surgical Management of the Axilla? MONICA MORROW, USA

Q & A

Saturday, 9th January 2021

15.50 - 21.15 Hrs Singapore Time

17

AstraZeneca Symposium 1 - Chairperson: JOLINE LIM, SINGAPORE

18:45 – 18:50 Welcome and Introductions JOLINE LIM, SINGAPORE

18:50 – 19:05 Evolving role of ADCs in the management of Her2+ mBC IAN KROP, USA

19:05 – 19:20 Optimizing treatment outcomes while treating Her2+ mBC patients with ADCs IAN KROP, USA

19:20 - 19:30 Q & A and live discussion

SESSION 3: Neo Adjuvant Therapy Chairperson: SOO CHIN LEE, SINGAPORE | REBECCA DENT, SINGAPORE

19:30 – 19:50 Tailoring Neoadjuvant / Adjuvant HER2+ Therapy in Breast Cancer PETER FASCHING, GERMANY

19:50 – 20:10 Tailoring/Neoadjuvant/Adjuvant TNBC Therapy in Breast Cancer LISA CAREY, USA

20:10 – 20:25 Q & A

Roche Symposium

An Emerging Paradigm in HER2-positive Breast Cancer Treatment

Chairperson: VIROTE SRIURANPONG, THAILAND

20:25 - 20:50 Advancing patient care in HER2-positive breast cancer SANDRA SWAIN, USA

20:50 - 21:05 Flexible Care: Moving Beyond the Hospital to the Community LEE SOO CHIN, SINGAPORE

21:05 - 21:10 Q & A and Live Interaction

21:10 Closing RemarkAPBCS 2021 COMMITTEE

18

15:55 – 16:00 Opening Remarks APBCS 2021 COMMITTEE

Novartis Symposium - Chairperson: LEE SOO CHIN, SINGAPORE

16:00 – 16:15 Transforming Treatment in Pre-menopausal HR+ HER20 ABC: Biological Differences and the role of CDK4/6i LU YEN SHEN, TAIWAN

16:15 – 16:30 Personalized Approach to Treatment: Practical Recommendations in Optimizing Treatment for HR+ HER-2 ABC Patients with PIK3CA Mutation LU YEN SHEN, TAIWAN

16:30 – 16:45 Q & A and live discussion

SESSION 4: Tumor Biology and AssessmentChairperson: TIRA TAN, SINGAPORE | IAIN TAN, SINGAPORE

16:45 – 17:05 Liquid BiopsiesNICHOLAS TURNER, UK

17:05 – 17:25 Molecular Profiling for Metastatic Breast Ca- When, How and Why?FABRICE ANDRE, FRANCE

17:25 – 17:45 What’s on the horizon for new drug development?GIUSEPPE CURIGLIANO, ITALY

17:45 – 17:50 Q & A

SESSION 5: Molecular Tumor BoardChairperson: SHAHEENAH DAWOOD, UAE | PAUL MAINWARING, AUSTRALIA

17:50 – 18:30 Tumor Board 1

PANELIST: GIUSEPPE CURLIGLIANO, ITALY | SEOCK-AH IM, SOUTH KOREA | SHAHEENAH DAWOOD, UAE | SAMUEL OW, SINGAPORE

Pfizer Symposium - Chairperson: SAMUEL OW, SINGAPORE

18:30 – 18:35 Welcome and Introductions SAMUEL OW, SINGAPORE

18:35 – 18:55 Management of HR+ HER2- mBC: From Clinical Evidence to Real-World Experience JANICE TSANG, HONG KONG

APBCS AGENGA – DAY 2

Sunday, 10th January 2021

15.55 - 21.45 Hrs Singapore Time

19

18:55 – 19:10 Case Presentation SHONA NAG, INDIA

19:10 – 19:15 Q & A and live discussion

SESSION 6: Advances in Clinical Management of Metastatic Breast CancerChairperson: JOLINE LIM, SINGAPORE | JACK CHAN, SINGAPORE

19:15 – 19:35 Novel approaches to HER2 + metastatic disease? Where do novel agents fit it? SEOCK-AH IM, SOUTH KOREA

19:35 – 19:55 Beyond first line CDK inhibition ER + MBC? SHOM GOEL, AUSTRALIA

19:55 – 20:15 New Therapies in TNBC ADITYA BARDIA, USA

AstraZeneca Symposium 2 - Chairperson: TIRA TAN, SINGAPORE

20:15 – 20:20 Welcome and Introductions TIRA TAN, SINGAPORE

20:20 – 20:45 Orchestrating the Sequencing strategies for HR+/Her2- mBC: Lessons learnt in the decade ADAM M. BRUFSKY, USA

20:45 – 21:00 Q & A and live discussion

SESSION 7: Interrogating the Immune System in Breast Cancer Chairperson: SHERENE LOI, AUSTRALIA | REBECCA DENT, SINGAPORE

21:00 – 21:15 Pathologist’s view on how to best to measure PD-L1? TAN PUAY HOON, SINGAPORE

21:15 – 21:30 New Biomarkers and Models Systems to Discern Sensitivity to Immune Checkpoint Inhibition CHARLES PEROU, USA

21:30 – 21:45 What biomarkers do I need to order for my patient with metastatic TNBC and when? Novel therapies on the horizon for TNBC SHERENE LOI, AUSTRALIA

21:45 Closing RemarkAPBCS 2021 COMMITTEE

2

Therapeutic indications

Tecentriq® (Atezolizumab) – Abbreviated Prescribing Information 3

Before prescribing TECENTRIQ®, please consult the full local prescribing information by visiting

www.roche.com.sg/en/pharma/tecentriq.html or by scanning the following QR code.

Published by Roche Singapore Pte Ltd 1 Paya Lebar Link, # 09-03 PLQ 1 Paya Lebar Quarter, Singapore 408533 Tel: +65 6735 0550 | Fax: +65 6737 5216

For HCPs only

M-SG-00000136-10-2020

Recommended by International guidelines 1

TECENTRIQ + nab-paclitaxel: The only cancer immunotherapy in PD-L1 + 1L mTNBC that demonstrated a clinically meaningful Overall Survival improvement

of 7.5 months2

Test your 1L mTNBC patients for PD-L1 status now

TECENTRIQ® + NAB-PACLITAXEL

KEEP PATIENTS WITH TNBC CONNECTED TO LIFE

Updated IMpassion 130 final OS data

Non Small Cell Lung Cancer (NSCLC): • TECENTRIQ®, in combination with Avastin, paclitaxel and carboplatin, is indicated for the treatment of patients with metastatic non-squamous NSCLC who had not received prior chemotherapy. • TECENTRIQ® is indicated for the treatment of patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. • Patients with EGFR or ALK genomic tumor aberrations should have disease progression on approved therapy for these aberrations prior to receiving TECENTRIQ®. • TECENTRIQ®, in combination with nab-paclitaxel and carboplatin is indicated for first line treatment of patients with metastatic non squamous NSCLC who do not have EGFR or ALK genomic tumor aberrations. Small Cell Lung Cancer (SCLC): • TECENTRIQ® in combination with carboplatin and etoposide, is indicated for the first line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). Triple Negative Breast Cancer (TNBC): • TECENTRIQ® in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic TNBC whose tumors have PD-L1 expression >1%, and who have not received prior chemotherapy for metastatic disease. Hepatocellular carcinoma (HCC): • TECENTRIQ® in combination with Avastin, is indicated for the treatment of patients with unresectable HCC who have not received prior systemic therapy.

Dosage and method of administration• TECENTRIQ® must be administered as an intravenous infusion under the supervision of a qualified healthcare professional. Do not administer as an IV push or bolus and do not co-administer other medicinal products through the same infusion line. The initial dose of TECENTRIQ® must be administered over 60 minutes. If the first infusion is tolerated, all subsequent infusions may be administered over 30 minutes.

• The recommended dose of TECENTRIQ® in monotherapy or combination therapy is: 840 mg administered by IV infusion every 2 weeks, or 1200 mg administered by IV infusion every 3 weeks, or 1680 mg administered by IV infusion every 4 weeks.

• TECENTRIQ® combination therapy: For the use of TECENTRIQ® in combination therapy, please also refer to the full prescribing information for the combination product. TECENTRIQ® should be administered prior to the combination therapy if given on the same day. 1L non-squamous NSCLC TECENTRIQ® in combination with Avastin, paclitaxel, and carboplatin During the induction phase, TECENTRIQ® is administered according to its dosing schedules by intravenous (IV) infusion, and Avastin, paclitaxel, and carboplatin are administered every 3 weeks for four or six cycles. The induction phase is followed by a maintenance phase without chemotherapy in which TECENTRIQ® is administered according to its dosing schedules by IV infusion, and Avastin is administered every 3 weeks. TECENTRIQ® in combination with nab-paclitaxel and carboplatin During the induction phase, TECENTRIQ® is administered according to its dosing schedules by IV infusion, and nab-paclitaxel and carboplatin are administered every 3 weeks for four or six cycles. For each 21-day cycle, nab-paclitaxel and carboplatin are administered on day 1. In addition, nab-paclitaxel is administered on days 8 and 15. The induction phase is followed by a maintenance phase without chemotherapy in which TECENTRIQ® is administered according to its dosing schedule. 1L ES-SCLC TECENTRIQ® in combination with carboplatin and etoposide During the induction phase, TECENTRIQ® is administered according to its dosing schedules by IV infusion, and carboplatin and etoposide are administered by IV infusion every three weeks for four cycles. Carboplatin and etoposide are administered on day 1 of each cycle, and etoposide is also administered on days 2 and 3. The induction phaste is followed by a maintenance phase without chemotherapy in which TECENTRIQ® is administered according to its dosing schedules by IV infusion. 1L TNBC TECENTRIQ® in combination with nab-paclitaxel. TECENTRIQ® is administered according to its dosing schedules by IV infusion and 100 mg/m2 nab-paclitaxel is administered on days 1, 8 and 15 during each 28-day cycle. Patients should be selected for treatment based on the tumor expression of PD-L1 confirmed by a validated test (see section 3.1.2 Clinical / Efficacy Studies). HCC TECENTRIQ® in combination with Avastin. TECENTRIQ® is administered according to its dosing schedules by IV infusion, and Avastin 15 mg/kg is administered every 3 weeks.

The safety and efficacy of alternating or switching between TECENTRIQ® and products that are biosimilar but not deemed interchangeable to TECENTRIQ® has not been established. Therefore, the benefit/risk of alternating or switching needs to be carefully considered. Safety reporting for potential undesirable effects: Please report any adverse events to the local Roche Adverse Event email at singapore.drugsafety@roche.com or call (65) 6735 0550. This will enable Roche to better understand the safety of TECENTRIQ®, and to provide appropriate information to Health Authorities, Healthcare Providers and patients.

References: 1. Gradishar, W. (2020, July 15). NCCN Clinical Practice Guidelines in Oncology - Breast Cancer. Retrieved 2020, from https://www2.tri-kobe.org/nccn/guideline/breast/english/breast.pdf. 2. Emens, LA, et al. IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab and nab-paclitaxel vs placebo and nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Annals of Oncology (2020) 31 (S4): S1148. doi.org/10.1016/j.annonc.2020.08.2244. 3.TECENTRIQ® Prescribing Information August 2020

THE 9TH ASIA-PACIFIC BREAST CANCER VIRTUAL SUMMIT INDUSTRY SATELLITE SYMPOSIUMSponsored by Pfizer Oncology

Management of HR+ HER2- mBC:From Clinical Evidence to Real-World Experience

Join regional thought-leaders in exploring key advances in the field of HR+ HER2- mBC, with a focus on real-world

data of CDK4/6 inhibitors, as well as how to eectively navigate the mBC patient journey in Asia.

10 January 2021(Sunday)

18:30–19:15 (GMT+8)

INVITATION

Pfizer Private Limited80 Pasir Panjang Road, #16-81/82, Mapletree Business City, Singapore 117372Tel: (65) 6403 8888 | Fax: (65) 6403 8868 | www.pfizer.com.sg

This symposium may contain information about investigational product(s)/indication(s) which are yet to be approved in your country. For healthcare professionals only. More information is available upon request.

PP-IBR-SGP-0066/05JAN2021

A G E N D A

Duration

5 mins

20 mins

15 mins

5 mins

Faculty

Dr Samuel Ow, Singapore

Dr Janice Tsang, Hong Kong

Dr Shona Nag, India

Dr Samuel Ow, Singapore

Topic

Introduction

Management of HR+ HER2- mBC: From Clinical Evidence to Real-World Experience

Case Presentation

Q&A

S P E A K E R S

Dr Samuel Ow Consultant

National University Cancer Institute Singapore

Dr Janice Tsang Honorary Clinical Assistant Professor

The University of Hong KongHong Kong

Dr Shona NagDirector of Oncology ServicesSahyadri Group of Hospitals

Pune, India

C H A I R P E R S O N

JOIN OUR SYMPOSIUM VISIT OUR PROFILE

LIFE

JOB NO.: 122983

For Healthcare Professionals Only. Please scan this QR code or visit https://www.novartis.com.sg/product-list/kisqali to access the full prescribing information

Novartis (Singapore) Pte Ltd20 Pasir Panjang Road, #10-25/28 Mapletree Business City, Singapore 117439Phone: +65 6722 6010 • Fax: +65 6323 4335 • www.novartis.comSG1909734699

PLATINUM SPONSORS

SILVER SPONSOR E-PARTNERS

MAIN SPONSORS

Inventing for life

24

APBCS.ORG

INDEX® Conferences & Exhibitions Organization Est.P.O. Box: 13636 | Dubai-UAE | INDEX Holding Headquarters Road # D-62 | Opposite Nad Al HamarTel: +971 4 5208888 | Fax: +971 4 3384193 | Email: info@apbcs.org

SEE YOU AGAININ

2022